论文部分内容阅读
目的 研究格列吡嗪控释片对2型糖尿病的临床降糖疗效。方法 单纯饮食和运动疗法控制不理想的2型糖尿病63例。其中新诊断的2型糖尿病31例,单用二甲双胍控制不满意的32例,疗程12周。结果 格列吡嗪控释片对新诊断的2型糖尿病患者的空腹、餐后2h血糖、HbAIC 较治疗前均有显著下降,分别从（9.78±1.32）、（13.68±1.55）、（8.98±1.26）降至（6.32±1.12）、（8.11±1.17）、（7.01±0.66）（P<0.01）。而且胰岛素水平从治疗前（35.1±3.9）降至（27.7±6.5）,ISI由治疗前（37.1±4.3）上升至（47.2±6.9）（P<0.01）。单纯服用二甲双胍控制不理想的患者,加用格列吡嗪控释片联合治疗后,其空腹、餐后2h血糖HbAIC同样有显著下降。分别从（9.56±1.81）、（13.24±1.53）、（8.84±1.31）降至（6.28±1.82）、（7.61±0.91）、（6.92±0.51）（P<0.01）。而胰岛素水平从治疗前（33.2±5.3）降至（26.9±4.9）,ISI由治疗前（35.8±6.7）上升至（45.7±5.9）。结论 格列吡嗪片控释片时2型糖尿病的治疗,不论单用或与二甲双胍联合使用均有显著降糖效果,并能提高胰岛素的敏感性,而且对甘油三酯也有不同程度降低。对体重指数无影响,对肝、肾功能无副作用。
Objective To study the clinical effect of glipizide controlled release tablets on type 2 diabetes. Methods Sixty-three patients with type 2 diabetes who were not controlled by simple diet and exercise therapy were enrolled. Among them, 31 cases of newly diagnosed type 2 diabetes mellitus were treated with metformin alone and 32 cases were unsatisfactory. The course of treatment was 12 weeks. Results Glipizide controlled-release tablets showed a significant reduction in fasting, postprandial 2-hour blood glucose and HbAIC in newly diagnosed type 2 diabetic patients from (9.78 ± 1.32), (13.68 ± 1.55) and (8.98 ± 1.26) to (6.32 ± 1.12), (8.11 ± 1.17) and (7.01 ± 0.66), respectively (P <0.01). Moreover, the insulin level decreased from 35.1 ± 3.9 to 27.7 ± 6.5 and the ISI increased from 37.1 ± 4.3 to 47.2 ± 6.9 before treatment (P <0.01). Metformin alone taking patients with unsatisfactory control, plus glipizide controlled-release tablets combined treatment, the fasting, 2h postprandial blood glucose HbAIC also significantly decreased. (P <0.01) from (9.56 ± 1.81), (13.24 ± 1.53) and (8.84 ± 1.31) to (6.28 ± 1.82), (7.61 ± 0.91) and (6.92 ± 0.51) respectively. The insulin level decreased from 33.2 ± 5.3 to 26.9 ± 4.9 and the ISI increased from 35.8 ± 6.7 to 45.7 ± 5.9 before treatment. Conclusion The treatment of type 2 diabetes mellitus with glipizide controlled-release tablets has significant hypoglycemic effect, either alone or in combination with metformin, and can improve insulin sensitivity, but also reduce the level of triglycerides to some extent. No effect on body mass index, no side effects on liver and kidney function.